BIOFIRE DEFENSE LLC - THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE REVEAL RAPID AST SYSTEM AS AN ANTIBIOTIC SUSCEPTIBILITY DIAGNOSTIC TEST TYPE OF COUNTERMEASURE TO DETERMINE THE TREATMENT FOR LIFE THREATENING URGENT INFECTIONS FROM PATIENT
Key Details
Description
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE REVEAL RAPID AST SYSTEM AS AN ANTIBIOTIC SUSCEPTIBILITY DIAGNOSTIC TEST TYPE OF COUNTERMEASURE TO DETERMINE THE TREATMENT FOR LIFE THREATENING URGENT INFECTIONS FROM PATIENT
Context & Analysis
On Dec 18, 2025, Department of Health and Human Services obligated $7,625,622 to BIOFIRE DEFENSE LLC for the overall objective of this contract is to advance the development of the reveal rapid ast system as an antibiotic susceptibility diagnostic test type of countermeasure to determine the treatment fo…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SALT LAKE CITY, UT. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.